If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Nuformix Sign Cannabinoid Agreement & Safestay discuss their Finals Results and John Meyer on Mining
Dr Dan Gooding, Chief Executive Officer of Nuformix (NFX) discusses the Strategic Cannabinoid Agreement they recently signed.
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested in pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities.
Nuno Sacramento, Chief Operating Officer of Safestay (SSTY) talks about some of the highlights from their final results today.
Safestay plc, the owner and operator of an international brand of contemporary hostels. Safestay has quickly become a leading player in the premium hostels market and have exciting expansion plans into key European gateway cities in 2019.
(Interview starts at 14 minutes 18 seconds)
John Meyer, Mining analyst and partner at SP Angel talks about:
Anglo-Asian Mining (AAZ)
Bushveld Minerals (BMN)
Metal Tiger (MTR)
SolGold (SOLG)
Savannah Resources (SAVP)
Bluebird Merchant Ventures (BMV)
(Interview starts at 22 minutes 56 seconds)